- Home
- PFG vs RPRX Comparison
PFG vs RPRX Comparison
Compare PFG & RPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PFG | RPRX |
|---|---|---|
| Founded | 1879 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Specialty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 18.6B | 16.2B |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | PFG | RPRX |
|---|---|---|
| Price | $87.67 | $39.70 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 10 | 3 |
| Target Price | ★ $88.40 | $46.00 |
| AVG Volume (30 Days) | 1.3M | ★ 4.3M |
| Earning Date | 10-27-2025 | 11-05-2025 |
| Dividend Yield | ★ 3.61% | 2.21% |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 6.91 | 1.75 |
| Revenue | ★ $15,800,800,000.00 | $2,349,844,000.00 |
| Revenue This Year | N/A | $37.13 |
| Revenue Next Year | $8.78 | $1.48 |
| P/E Ratio | ★ $12.66 | $22.68 |
| Revenue Growth | ★ 12.33 | 3.70 |
| 52 Week Low | $68.39 | $24.05 |
| 52 Week High | $90.31 | $41.24 |
Technical Indicators
Market Signals| Indicator | PFG | RPRX |
|---|---|---|
| Relative Strength Index (RSI) | 67.39 | 57.50 |
| Support Level | $83.50 | $39.24 |
| Resistance Level | $85.51 | $40.50 |
| Average True Range (ATR) | 1.86 | 0.91 |
| MACD | 0.25 | -0.08 |
| Stochastic Oscillator | 96.65 | 76.02 |
Price Performance
Historical ComparisonAbout PFG Principal Financial Group Inc
Principal Financial Group Inc is a financial services provider. It offers various financial products and services including retirement, asset management, and workplace benefits and protection solutions to individuals and institutional clients. The company, along with its subsidiaries, operates in the following reportable segments; Retirement and Income Solutions, Principal Asset Management, and Benefits and Protection. Maximum revenue is generated from the Retirement and Income Solutions segment which provides workplace savings and retirement solutions, banking, trust and custodial services, individual variable annuities (including RILAs), pension risk transfer, and investment services to businesses, their employees, and other individuals.
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.